Table 4. Major adverse reactions.
| CPT-P | VDS-P | CPT | |
|---|---|---|---|
| (n=126) | (n=120) | (n=127) | |
| Leucopenia (grade 4) | 8 (6%) | 4 (3%) | 2 (2%) |
| Neutropenia (grade 4) | 46 (37%) | 65 (54%) | 10 (8%) |
| – Febrile neutropenia | 13 (10%) | 13 (11%) | 8 (6%) |
| Thrombocytopenia (grade 4) | 4 (3%) | 1 (1%) | 0 (0%) |
| Anaemia (grade 4) | 2 (2%) | 1 (1%) | 1 (1%) |
| GOT↑ (grades 3 and 4) | 0 (0%) | 1 (1%) | 0 (0%) |
| GPT↑ (grades 3 and 4) | 1 (1%) | 1 (1%) | 0 (0%) |
| BUN↑ (grades 3 and 4) | 2 (2%) | 2 (2%) | 0 (0%) |
| Creatinine↑ (grades 3 and 4) | 0 (0%) | 1 (1%) | 0 (0%) |
| Diarrhoea (grades 3 and 4) | 15 (12%) | 4 (3%) | 19 (15%) |
| Nausea/vomiting (grades 3 and 4) | 41 (33%) | 27 (23%) | 12 (9%) |
| Infection (grades 3 and 4) | 4 (3%) | 1 (1%) | 6 (5%) |
CPT=irinotecan; P=cisplatin; VDS=vindesine; GOT=glutamic oxaloacetic transaminase; GPT=glutamic pyruvic transaminase; BUN=blood urea nitrogen.